Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Net Income towards Common Stockholders: 2011-2025

Historic Net Income towards Common Stockholders for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$5.2 million.

  • Abeona Therapeutics' Net Income towards Common Stockholders rose 82.95% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.2 million, marking a year-over-year increase of 194.92%. This contributed to the annual value of -$63.7 million for FY2024, which is 17.53% down from last year.
  • Per Abeona Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$5.2 million for Q3 2025, which was down 104.54% from $113.7 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Net Income towards Common Stockholders high stood at $113.7 million for Q2 2025, and its period low was -$46.7 million during Q4 2021.
  • In the last 3 years, Abeona Therapeutics' Net Income towards Common Stockholders had a median value of -$12.0 million in 2025 and averaged -$3.8 million.
  • As far as peak fluctuations go, Abeona Therapeutics' Net Income towards Common Stockholders plummeted by 247.25% in 2024, and later surged by 945.23% in 2025.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Net Income towards Common Stockholders stood at -$46.7 million in 2021, then surged by 84.79% to -$7.1 million in 2022, then crashed by 133.80% to -$16.6 million in 2023, then surged by 44.22% to -$9.3 million in 2024, then skyrocketed by 82.95% to -$5.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$5.2 million for Q3 2025, versus $113.7 million for Q2 2025 and -$12.0 million for Q1 2025.